NCT00426153View on ClinicalTrials.gov

Octreotide in Severe Polycystic Liver Disease

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Polycystic Kidney, Autosomal DominantPolycystic Liver DiseaseHepatomegalyLiver DiseasesKidney, PolycysticAbdominal Pain
Interventions
DRUG

Octreotide

Participants received Octreotide LAR® Depot injections (up to 40 mg)intramuscularly every 28 days (+/- 5 days) for one year

DRUG

Placebo

Participants received an injection of placebo (sham) medication intramuscularly every 28 days (+/- 5 day) for one year

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

collaborator

National Center for Research Resources (NCRR)

NIH

lead

Mayo Clinic

OTHER